Health Care • Medicinal Chemicals and Botanical Products
$208.79 ▲ +0.29
(+0.14%)
MKT CAP: $324.98B • VOL: 4.59M
52W L $142 52W H $214
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$175
MEDIAN
$234
MEAN
$238
HIGH
$284
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PM TAPE
PM // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $252.64 | $240.11 | 2025-02-14 | $190.00 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $263.08 | $246.37 | 2025-02-06 | $196.26 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $238.02 | $229.67 | 2025-01-29 | $200.44 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $212.97 | — | 2025-01-17 | $204.61 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $183.74 | $198.35 | 2025-01-09 | $185.82 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $248.46 | $217.14 | 2024-12-18 | $181.65 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $202.53 | $210.88 | 2024-12-04 | $194.17 | -4.3% | 48% | C |